Market Currents

• Tuesday, October 20, 2009

• 16:16 PM Gilead Sciences (GILD): Q3 EPS of $0.78 beats by $0.11. Revenue of $1.8B (+31%) vs. $1.75B. Shares -0.8% AH. (PR) 1 Comment
• 00:10 AM Notable post-market earnings: AMLN, CHRW, CNI, CREE, GILD, INFN, ISRG, NBR, PLCM, SNDK, SLM, STX, STM, SYK, TUP, WLT, YHOO Comment!

• Tuesday, September 29, 2009

• 17:55 PM With markets up almost 50% since March, fund managers are generally treading carefully. Here are some stocks the group says may still have some juice: Commodities (RIG, STLD), healthcare (ABT, GILD), business spending (AMD, ASML), and top fliers that were left behind (BMY, VZ, WMT). 1 Comment

• Wednesday, July 22, 2009

• 09:00 AM Premarket gainers: ONXX +32%. ATHR +11%. AAI +9%. SBUX +9%. BDSI +8%. CKSW +6%. AKRX +4%. AAPL +4%. STX +4%. HGSI +4%.
  Losers: AMD -14%. PPDI -13%. AAN -12%. CIT -8%. RSH -7%. KEY -6%. WFC -6%. HEB -6%. SAY -6%. MS -5%. ERX -4%. SLM -4%. YHOO -4%. CVBF -4%. RCL -4%. GILD -4%. BK -4%. CHU -4%. SQNM -4%. Comment!

• Tuesday, July 21, 2009

• 16:26 PM Gilead Sciences (GILD): Q2 EPS of $0.69 beats by $0.08. Revenue of $1.7B (+29%) vs. $1.6B. Shares -1.8% AH. (PR) Comment!
• 00:10 AM Notable earnings after Tuesday's close: AAPL, AMD, AMLN, ATHR, BXP, CHRW, FULT, GILD, ILMN, LLTC, NBR, PPDI, PTV, QLGC, RHI, SBUX, SLM, STX, SYK, VFC, YHOO Comment!

• Monday, April 27, 2009

• 09:02 AM Premarket gainers on swine-flu speculation: NVAX +133%. SVA +63%. BCRX +58%. AVII +35%. VICL +32%. QDEL +26%. HGSI +19%. RAD +15%. CRXL +7%. BLUD +7%. HUM +6%. BAX +4%. GSK +4%. THC +4%. GILD +4%. 1 Comment

• Wednesday, April 22, 2009

• 09:00 AM Premarket gainers: PFCB +17%. SNDK +8%. F +8%. MEDX +7%. GERN +6%. GILD +6%. SLW +5%. ELN +5%. DNDN +4%. STEM +4%. GM +5%. BA +4%. TROW +4%. BRCD +4%.
  Losers: PPDI -19%. FRE -12%. FITB -9%. RF -9%. COF -8%. PUK -9%. MS -8%. JAH -8%. ETFC -8%. HBAN -8%. PXP -7%. TXT -7%. VNO -6%. ILMN -6%. AMD -6%. USB -5%. WFC -5%. TCK -5%. BHP -5%. HBC -5%. AKS -5%. HIG -5%. Comment!

• Tuesday, April 21, 2009

• 17:05 PM Gilead Sciences (GILD): Q1 EPS of $0.66 beats by $0.07. Revenue of $1.53B. Shares +3.8% AH. (PR) Comment!
• 15:10 PM Notable earnings after Tuesday's close: ALTR, AMD, AMP, BRCM, CBST, CENX, CHRW, COF, CREE, FULT, GILD, HCBK, ILMN, MOLX, NBR, NSC, PPDI, SNDK, STX, TEX, WMS, YHOO Comment!
• 00:10 AM Notable earnings after Tuesday's close: ALTR, AMD, AMP, BRCM, CBST, CENX, CHRW, COF, CREE, FULT, GILD, HCBK, ILMN, MOLX, NBR, NSC, PPDI, SNDK, STX, TEX, WMS, YHOO Comment!

• Friday, April 3, 2009

• 09:00 AM Premarket gainers: IRE +43%. AIB +41%. RIMM +26%. BBI +20%. RBS +13%. ING +8%. GILD +7%. BCS +7%. KIM +6%. AAUK +5%. RAD +4%. S +4%. LVS +4%. SI +4%. JASO +4%. UBS +4%. MGM +4%.
  Losers: NVO -8%. IIJI -8%. AU -8%. FITB -5%. MU -5%. ASX -4%. CDE -4%. MOT -4%. HMY -4%. Comment!

• Monday, March 16, 2009

• 08:50 AM Japan's Astellas Pharma withdraws its $16/share hostile offer for CV Therapeutics (CVTX), saying it can't compete with Gilead Sciences's (GILD) $20/share bid. CVTX -4.8% premarket. GILD +0.7%. Comment!

• Thursday, March 12, 2009

• 09:05 AM Gilead Sciences (GILD) offers to buy CV Therapeutics (CVTX) for $20/share in a deal valued at $1.4B. Gilead expects the purchase to close in Q2 and add to earnings by 2011. Premarket: GILD -3.7%. CVTX +27.5%. Comment!
• 09:01 AM Premarket losers: MTG -23%. MT -6%. AAUK -6%. SPWRA -5%. VIP -5%. BCS -5%. GILD -4%. X -3%. AZ -3%. BHP -3%. Comment!

• Tuesday, January 27, 2009

• 16:17 PM Gilead Sciences (GILD): Q4 EPS of $0.56 beats by $0.01. Revenue of $1.43B (+30.5%) in-line. Shares -0.5% AH. (PR) Comment!